In Brief: Laserscope
This article was originally published in The Gray Sheet
Executive SummaryLaserscope: Completes acquisition of Heraeus Surgical from parent company Heraeus MED, GmbH. A definitive agreement for the deal, valued at about $18.4 mil., was announced in April ("The Gray Sheet" April 29, I&W-3). Laserscope expects to cut operating expenses of the combined firm over the next year by "more than $3 mil.," Laserscope President and CEO Robert McCormick states in a Sept. 3 release...
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.